Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden.
作者:
主题词
人类(Humans);抗体, 单克隆(Antibodies, Monoclonal);超重(Overweight);治疗结果(Treatment Outcome);银屑病(Psoriasis);患病代价(Cost of Illness);疾病严重程度指数(Severity of Illness Index);体重(Body Weight);生物制品(Biological Products)
DOI
10.1080/14712598.2024.2325547
PMID
38444107
发布时间
2024-03-29
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文